Ningbo Menovo Pharmaceutical's subsidiary, Shakuba Qu Xie Losartan Sodium API, passed the CDE technical review.

Ningbo Menovo Pharmaceutical (603538.SH) announced that its wholly-owned subsidiary, Xuan Cheng Ningbo Menovo Pharmaceutical Co., Ltd. (referred to as "Xuan Cheng Ningbo Menovo Pharmaceutical"), has received approval from the National Medical Products Administration for the production and sale of raw materials for sacubitril valsartan sodium, used to treat primary hypertension. The sacubitril valsartan sodium raw materials produced by Xuan Cheng Ningbo Menovo Pharmaceutical have passed the CDE technical evaluation, indicating that the raw materials meet national drug evaluation technical standards and can be sold in the domestic market. This will further enhance the subsidiary's product line, expand the company's business scope, and strengthen the company's advantage in integrated production of raw materials and formulations.